This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Krause, P.R. & Klinman, D.M. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nature Med. 6, 451–454.
Finger, R., et al. Age-specific incidence of chickenpox. Public Health Rep. 109, 750–755 (1994).
Watson, B. et al. Modified chickenpox in children immunized with the OKA/Merck varicella vaccine. Pediatrics 1993; 81:17–22 (1993).
White, C.J. et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Ped. Infect. Dis. J. 11, 19–23 (1992).
Gershon, A. et al. Immunization of healthy adults with live attenuated varicella vaccine. J. Infect. Dis. 158, 132–137 (1998).
Hardy, I. et al. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. N. Engl. J. Med. 325, 1545–1550 (1991).
Johnson, C. et al. A long-term prospective study of varicella vaccine in healthy children. Pediatrics 100, 761–766 (1997).
Shapiro, E., Vazquez, M., LaRussa, P., Steinberg, S. & Gershon, A. Protective efficacy of varicella vaccine. in 24th International Herpes Virus Workshop abstract 13.030 (Boston, Massachusetts, 1999).
Sharrar, R. et al. The Postmarketing Safety Profile of Varicella Vaccine. Vaccine In the press.
LaRussa, P., Steinberg, S., Shapiro, E., Vazquez, M. & Gershon, A. Viral Strain Identification in varicella vaccinees with disseminated rashes. Ped. Infect. Dis. In the press.
LaRussa, P. Characterization of a restriction site polymorphism present in DNA from the vaccine strain of varicella zoster virus (VZV). Abstract 453 presented at the 15th International Herpes virus workshop. Washington, D.C.. August 2, 1990.
Arvin, A.M., Pollard, R.B., Rasmussen, L. & Merigan, T. Selective impairment in lymphocyte reactivity to varicella-zoster antigen among untreated lymphoma patients. J. Infect. Dis. 137, 531–540 (1978).
Brunell, P., Gershon, A.A., Uduman, S.A. & Steinberg, S. Varicella-zoster immunoglobulins during varicella, latency, and zoster. J. Infect. Dis. 132, 49–54 (1975).
Gershon, A.A., Steinberg, S., Gelb, L. & NIAID-Collaborative-Varicella-Vaccine-Study-Group. Live attenuated varicella vaccine: efficacy for children with leukemia in remission. JAMA 252, 355–362 (1984).
Williams, V., Gershon, A. & Brunell, P. Serological response to varicella-zoster virus membrane antigens measured by indirect immunofluorescence. J. Infect. Dis. 130, 669 (1974).
Brunell, P.A. Oka from a generalized rash in a vaccinated child. Pediatrics 106, e28 (2000).
Weibel, R.E. et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N. Engl. J. Med. 310, 1409–1415 (1984).
Kuter, B. et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 9, 643–647 (1991).
Moffat, J.F. et al. Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in α-herpesvirus virulence demonstrated in the SCID-hu mouse. J. Virol. 72, 965–974 (1998).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Seward, J., Jumaan, A. & Schmid, S. Varicella vaccine revisited. Nat Med 6, 1298–1299 (2000). https://doi.org/10.1038/82068
Issue Date:
DOI: https://doi.org/10.1038/82068